- Dec 19, 2016

New clinical study for children with AML aims to kill leukemia cells and minimize cardiac damage

Cooper is leading a new nationwide clinical trial, conducted within the Children's Oncology Group (COG), for children and adolescents with relapsed acute myelogenous leukemia (AML) to test a drug, CPX-351, which has been designed to kill leukemia cells while minimizing damage to the heart.

Study shows potential of new treatment strategies for most common childhood cancer

Promising target for CAR T cells helps cancer trick the immune system

Palliative Care Important for Young Patients During ‘Identity Development’

Scientists discover new Achilles heel of leukemia cells

Promising investigational therapy improves survival in aggressive childhood brain tumor

Childhood cancer mortality has fallen significantly in the US, but disparities have emerged

St. Jude scientists identify T-cell differentiation nodes to improve cancer-killing

Analysis shows high rate of ‘significant’ health problems in childhood cancer survivors

Fusion oncoprotein forces cell fates toward rhabdomyosarcoma

“DNA loops” in pediatric brain tumors double relapse risk

Recent Posts

New clinical study for children with AML aims to kill leukemia cells and minimize cardiac damage

Archive

Search By Tags